Get the Stockscreener App
4.70
2.95%
0.13
Macrogenics Inc stock is traded at $4.70, with a volume of 579.68K.
It is up +2.95% in the last 24 hours and up +20.33% over the past month.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
See More
Previous Close:
$4.57
Open:
$4.6
24h Volume:
579.68K
Relative Volume:
0.51
Market Cap:
$298.43M
Revenue:
$157.08M
Net Income/Loss:
$-70.36M
P/E Ratio:
-4.2281
EPS:
-1.1116
Net Cash Flow:
$-71.69M
1W Performance:
+1.84%
1M Performance:
+20.33%
6M Performance:
+159.94%
1Y Performance:
+245.96%
1-Day Range:
$4.39
$4.735
1-Week Range:
$4.39
$5.06
52-Week Range:
$1.29
$5.08
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
4.695 | 290.48M | 157.08M | -70.36M | -71.69M | -1.1116 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.79 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.13 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Upgrade | B. Riley Securities | Neutral → Buy |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations - The Sun Malaysia
MacroGenics completes sale of manufacturing operations to Bora - Investing.com
MacroGenics sells its drug-making operations to Bora for $122.5M - Stock Titan
MacroGenics (MGNX) Financials 2026Income Statement and Balance Sheet - MarketBeat
Macrogenics | 4: Statement of changes in beneficial ownership of securities-Director O'Brien Federica F. - Moomoo
MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2500 Growth Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2000 Value Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2000 Growth Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 3000E Index - marketscreener.com
Enterprise value to revenue forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 3000E Value Benchmark - marketscreener.com
Price to earnings forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
Enterprise value to revenue forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
Enterprise value to EBITDA forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
Enterprise value to EBIT forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
Enterprise value to EBIT forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
Price to sales forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
Price to book forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
MGNX Forecast — Price Target — Prediction for 2027 - TradingView
MacroGenics, Inc. Actuals & Estimates (NASDAQ:MGNX) - TradingView
M55 Forecast — Price Target — Prediction for 2027 - TradingView
A1W6ND Forecast — Price Target — Prediction for 2027 - TradingView
MacroGenics Inc (MGNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment (NASDAQ:MGNX) - Seeking Alpha
MacroGenics To Receive $24.5 Million Milestone From Sanofi For TZIELD Approval - Pulse 2.0
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval - The Manila Times
MacroGenics stock rises on $24.5M Sanofi milestone payment - Investing.com
MacroGenics to receive $24.5M milestone from Sanofi on FDA approval - Investing.com Australia
MacroGenics stock rises on $24.5M Sanofi milestone payment By Investing.com - Investing.com Nigeria
Sanofi (SNY) Drives $24.5M Milestone Payment to MacroGenics - GuruFocus
MacroGenics to Receive $24.5 Million in Regulatory Milestone Payment - marketscreener.com
MacroGenics to Receive $24.5 Million Milestone Payment Following FDA Accelerated Approval of Sanofi’s TZIELD for Children with Stage 3 Type 1 Diabetes - Quiver Quantitative
Sanofi’s TZIELD approval triggers $24.5M payment to MacroGenics - Stock Titan
MacroGenics (MGNX) Gains 4.3% as Shares Test Key Resistance LevelsOrder Block - dars.gov.et
MacroGenics Inc (MGNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MacroGenics StockThursday technical snapshot after strong year-to-date rebound - AD HOC NEWS
MacroGenics Inc (MGNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MacroGenics Inc (MGNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MacroGenics Inc (MGNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MacroGenics Inc (MGNX) Institutional Confidence - TradingKey
MacroGenics Inc (MGNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
MacroGenics Inc (MGNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MacroGenics Inc Stock (US5562221046): Valuation metrics in focus after recent biotech swing - Ad-hoc-news.de
How The MacroGenics (MGNX) Story Is Shifting With ADC Pipeline Bets And 2026 Data Risks - Yahoo Finance
Millennium Group and Israel Englander report 3.44M MGNX shares (5.4%) - Stock Titan
MacroGenics eyes $200M cash boost, 2028 runway ahead of cancer pipeline updates - MSN
MacroGenics (MGNX) Slips 1.19% as Biotech Stock Tests Key SupportPoint of Control - Město Břeclav
MacroGenics expands ZYNYZ royalty deal with Sagard, secures $60M upfront - MSN
MacroGenics Inc stock (US5562221046): shares ease after strong year-to-date run amid biotech volatil - AD HOC NEWS
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Macrogenics Inc Stock (MGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HEIDEN WILLIAM K | Director |
Aug 19 '25 |
Buy |
1.52 |
50,500 |
76,760 |
61,500 |
| HEIDEN WILLIAM K | Director |
Aug 20 '25 |
Buy |
1.49 |
49,500 |
73,755 |
111,000 |
| Koenig Scott | Director |
Aug 13 '25 |
Option Exercise |
0.00 |
52,829 |
0 |
830,244 |
1.21%
3.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):